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ABSTRACT 
Objective. Although the remission criteria for generalized anxiety are well defined, there is not 
much data available on the point prevalence of remission. The Measuring Impact of Remission in 
Anxiety Disorders in Belgium (MIRABEL) study is a naturalistic study designed to document the 
point prevalence of remission in patients treated for general anxiety and potential factors 
affecting this prevalence. Methods. The study population consisted of 618 adult outpatients 
being treated for generalized anxiety. The sample is defined by the key symptoms of generalized 
anxiety disorder rather than by fulfilling the exact DSM-IV- TR diagnostic criteria. Remission was 
defined as a Hamilton Anxiety Scale (HAM-A) score of less than or equal to 7. To reduce the 
interrater reliability, the HAM-A was assessed by the attending physicians who had no specific 
training. Factors investigated as possibly related to remission included sociodemographic, 
disease and treatment characteristics. Results. The point prevalence of remission in the study 
population was estimated at 13.3%. Remission prevalence varied with occupational status and 
severity of the current anxiety episode. Remission prevalence was lower in the presence of 
comorbidity and was proportional to the number of comorbid symptoms. Remitters took fewer 
medications but were treated longer. Remission prevalence was higher in patients who were 
taking antidepressants, but was lower in patients who were taking sedatives. Conclusions. These 
findings underline the poor prognosis of generalized anxiety. 
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Generalized anxiety is one of the most common anxiety disorders with a 12-month prevalence of 
2.0 (Kessler et al. 2012) and a point prevalence of 13.4% in Belgian primary care (Ansseau et al. 
2008). The burden of generalized anxiety on society is substantial, not only due to the direct 
costs of treatment but also due to the indirect costs resulting from the impaired functioning in 
all aspects of life (Hoffman et al. 2008). 
In the treatment of generalized anxiety, both cognitive psychotherapy and pharmacotherapy 
have been demonstrated to be effective (Davidson 2009; Bandelow et al. 2012). It is 
acknowledged that in generalized anxiety remission should be the primary treatment goal, and 
remission criteria have been established and implemented in clinical trials (Ballenger 2001; 
Doyle and Pollack 2003). 
Despite the fact that generalized anxiety is a common and treatable disorder and the fact 
that remission criteria are well described, data do not seem to exist on the prevalence of 
remission in “real world” clinical settings. To amend this lack, the Measuring Impact of 
Remission in Anxiety disorders in Belgium (the MIRABEL) study was launched and the first 
results were reported in this paper. The study is primarily aimed at establishing remission rates 
in patients currently treated for generalized anxiety both in primary and psychiatric care 
settings. In addition, the purpose of this study was to analyse the potential impact of 
sociodemographic, disease and treatment factors on the point prevalence of remission. 
Methods and materials 
OVERALL STUDY DESIGN AND PARTICIPANTS 
MIRABEL is an open-label, cross-sectional, observational, point-prevalence study of remission in 
adult patients currently receiving treatment for generalized anxiety. General practitioners (GPs) 
and psychiatrists in Belgium were invited to screen their patients with generalized anxiety during 
a consultation between October 2006 and December 2007. In order to be included in the study, 
patients had to satisfy the following criteria: (1) 18 years of age and over, (2) outpatient status, 
(3) treatment for generalized anxiety, and (4) written informed consent. Although not a 
mandatory criterion, we aimed to include patients who had been in treatment for a minimum of 3 
and a maximum of 12 months, since the focus of the study was on patients in the acute phase of 
their disease. Treatments remained entirely at the discretion of the attending physicians. The 
research was conducted in accordance with the current version of the Declaration of Helsinki. 
ASSESSMENT PROCEDURE AND TOOLS 
As required by the protocol, having obtained written informed consent from their patient, all 
participating physicians used the same case report form (CRF) to collect and verify the patient 
information. To ensure that the data collected were accurate, consistent, complete, and reliable, a 
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representative of the sponsor paid periodic visits to the investigation site while the study was in 
progress and reviewed the data thoroughly. All missing, contradictory, and critical data were 
identified and then were clarified by the investigator(s). 
Symptom severity was assessed by the Hamilton Anxiety Scale (HAM-A) (Hamilton 1959), an 
observer-rated inventory consisting of 14 items, each gauging the severity of a specified set of 
symptoms on a 5-point Likert scale ranging from 0 (not present) to 4 (severe). As it was our goal 
to determine the prevalence of remission in patients with generalized anxiety receiving 
treatment, the HAM-A variable used in the definition of remission was taken as the primary 
variable. By definition, we categorized a patient as being in remission if HAM-A less than or equal 
to 7 (7,9). No specific training was provided for the participating physicians. However, an 
investigator guide, including a short manual for the HAM-A, was provided. 
To ease the investigator in verifying the symptoms of generalized anxiety and in recording the 
comorbid symptoms, the CRF captured the specific generalized anxiety symptoms (i.e., excessive 
anxiety and worry for at least 6 months, difficulty to control the worry, fatigue, difficulty 
concentrating, irritability, muscle tension, and insomnia) as well as the specific symptoms of 
depression (i.e. depressive mood and anhedonia) and other anxiety disorders (panic disorder, 
agoraphobia, specific phobia, social phobia, obsessive-compulsive disorder, or posttraumatic 
stress disorder). 
Other variables that are likely to influence remission rates were also recorded for each patient; 
sociodemographic, disease and treatment factors, individual scores on the 14-item, and self-
reported Hospital Anxiety and Depression (HADS) reflecting comorbidity with depression. Self-
rating scales offer the possibility to find out whether the patients and physicians rate the 
symptoms in the same way. Since the exact duration of the previous generalized anxiety episodes 
was not assessed in the CRF, the number of previous episodes was not involved in the results. 
STATISTICAL ANALYSIS 
Quantitative variables and scores were expressed as mean ± standard deviation (SD), whereas 
categorical variables were described in a frequency table. Prevalence estimates (%) were 
associated with their 95% confidence intervals (95% CI). Mean values were compared by one-
way analysis of variance (ANOVA) or Student’s t-test, and proportions by the chi-squared test for 
contingency tables. The nonparametric Kruskal–Wallis and Wilcoxon tests were used if normality 
assumptions were not fulfilled. Cut-off points between remitters and nonremitters were obtained 
by logistic regression analysis. Calculations were always carried out on the maximum number of 
data available, and the missing data were not replaced. Results were considered to be significant 
at the 5% critical level (p < 0.05). Data analyses were carried out using SAS (version 9.1 for 
Windows) and S-PLUS (version 6.2) statistical packages. 
Assuming a point prevalence of remission of generalized anxiety between 20% and 40% as 
reported in the literature (Kjernisted and Bleau 2004; Ballenger 2004), a sample size of 900 
patients would ensure a statistical precision of less than or equal to 5% in the prevalence 
estimate with a 95% confidence. 
Published in : International Journal of Psychiatry in Clinical Practice (2013), vol. 17, n°2, pp. 
90–97 
DOI:10.3109/13651501.2013.784789 






A total of 618 patients with generalized anxiety were included in the study and were recruited by 
211 physicians (157 GPs and 54 psychiatrists). Among these patients, 365 (59.1%) were treated 
by a GP (primary care) and 253 (40.9%) by a psychiatrist (secondary care). The mean number of 
patients included by GPs was 5.0 ± 1.1 patients (range: 1–7) while the mean number included by 
psychiatrists was 7.4 ± 3.5 patients (range: 1–13) which differed significantly (t(43.29)= -4.43, p 
< 0.001). HAM-A scores were available for 607 patients (98.2%). Remission (HAM-A ≤ 7) was 
observed in 81 subjects, yielding a point prevalence of 13.3% (95% CI: 10.6%– 16.1%). The HAM-
A mean score was 19.3 ± 9.5. Remission rates did not differ in primary and psychiatric care 
(12.8% vs. 14.1%, p = 0.64). 
DEMOGRAPHY 
The demographic characteristics of the study population are displayed in 
Table I. Except for occupational status (p < 0.0001, 2 (1) = 31.98), characteristics of remitters 
and non-remitters were similar. Unfortunately demographic variables are missing in up to 1.3% 
of the patients. 
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Table 1. Demographic characteristics of the patient population with generalized anxiety (n = 618) and 





Variable Total No Yes p-value Test statistic 
Age (yrs) Mean ± SD  
46.8 ± 14.3 
 







T = 0.21 
Gender      
Female 402 (65.9) 341 (86.5) 53 
(13.5) 
0.92 2 = 0.0092 
Male 208 (34.1) 178 (86.8) 27 
(13.2) 
  
Native language      
Dutch 291 (47.1) 244 (85.3) 42 
(14.7) 



















2 = 0.046 
With partner/family 461 (75.2) 393 (86.6) 61 
(13.4) 
  
Education      
No formal diploma 14 (2.3) 13 (92.9) 1 (7.1) 0.70 2 = 2.98 
Primary 52 (8.5) 46 (88.5) 6 
(11.5) 
  
Lower secondary 202 (33.0) 173 (88.3) 23 
(11.7) 
  
Upper secondary 143 (23.4) 122 (86.5) 19 
(13.5) 
  



















2 = 31.98 
Allowance (any) 150 (24.4) 140 (95.2) 7 (4.8)   
Self-employed 38 (6.2) 34 (89.5) 4 
(10.5) 
  
Blue collar worker 84 (13.7) 75 (90.4) 8 (9.6)   
White collar worker 145 (23.6) 119 (83.8) 23 
(16.2) 
  
Middle management 30 (4.9) 26 (89.7) 3 
(10.3) 
  
Higher management 12 (2.0) 9 (75.0) 3 (25.0)   
Retired 106 (17.2) 87 (84.5) 16 (15.5)   
 
DISEASE FACTORS 
One hundred and sixty-seven (27.4%) patients fulfilled the exact diagnostic criteria according the 
DSM-IV-TR for generalized anxiety disorder, while the majority of the other patients showed the 
symptoms as described in the DSM- IV-TR; the most prevalent symptoms were excessive anxiety 
and worry for at least 6 months (81.9%), insomnia (73.1%), difficulty to control the worry 
(69.0%), fatigue (67.0%), irritability (63.4%), difficulty concentrating (61.8%), restlessness 
(53.9%) and muscle tension (47.3%), respectively. Forty-five (10%) patients presented all 
symptoms. The mean number of symptoms per patient was 5.2 ± 1.8. 
As seen in Table II, the initial severity of the current generalized anxiety episode was markedly 
different in remitters and non-remitters (p < 0.0001). The mean number of symptoms was 
higher for patients treated by a psychiatrist compared to patients treated by a GP (6.4 ± 1.3 vs. 
4.8 ± 1.7, p > 0.0001). Patients with severe generalized anxiety disorder were more often seen by 
a psychiatrist than by a GP (32.0% vs. 20.2%, p = 0.0015). Data on the initial severity of the 
current generalized anxiety episode were missing in 0.6%. 
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Globally, 88.2% of the patients presented with comorbid symptoms in the two weeks preceding 
the assessment. About 67.5% of the patients reported depressive mood and anhedonia and 
53.1% of the patients had typical symptoms of other anxiety disorders (panic disorder, 
agoraphobia, specific phobia, social phobia, obsessive compulsive disorder, or posttraumatic 
stress disorder), while 34.1% (211) of the patients presented with both depressive 
mood/anhedonia and core symptoms of other anxiety disorders. The patients in remission had 
fewer comorbid symptoms than the non-remitters (0.9 ± 0.9 vs. 2.0 ± 1.3, p < 0.0001, T(1) = 9.05). 
Accordingly, the prevalence of remission was low when comorbid symptoms were present (43.1% 
vs. 9.4%, p < 0.0001, T(1) = 62.36). 
The mean HADS (assessing comorbidity with depression scale) anxiety score was 12.1 ± 4.5 
(range: 0–21) and the mean HADS depression score was 9.3 ± 4.8 (range: 0–21). Remitters showed 
less severe symptoms of anxiety (6.6 ± 4.0 vs. 13.0 ± 3.9, p < 0.0001, T(1) = 13.59) and of 
depression (4.1 ± 3.5 vs. 10.1 ± 4.5, p < 0.0001, T(1) = 13.95) than that of non-remitters. The 
distributions of the HADS anxiety and depression scores for the two groups are displayed in Figure 
1. The cut-off points for the HADS were found to be equal to 9.0 for anxiety and 5.9 for depression, 
respectively. In other words a HADS anxiety score higher than 9 was seen more frequently in non-
remitters than in remitters and similarly for a HADS depression score higher than 5.9. Furthermore, 
the HADS anxiety and depression were correlated with the HAM-A score (r= 0.62, p < 0.0001 and r 
= 0.58, p < 0.0001). The HADS anxiety and depression scores were missing in 1.0% and 0.6% of the 
participants, respectively. 
Table 2. Disease factors in the patients population with generalized anxiety (n= 618) and comparison 






Variable Total          No            Yes       p-value     Test Statistics 
Initial severity of the current GAD episode 
Mild 75 (12.4) 53 (69.7) 23 (30.3) < 0.0001 2 = 22.13 
Moderate 385 (62.6) 338 (89.9) 38 (10.1)   









Figure 1. Distribution of the HADS anxiety score (left) and HADS depression score (right) in remitters and 
non-remitters. Cut-off points equal 9 for HADS anxiety and 5.9 for HADS depression. 
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Treatment, consisting of medication, psychotherapy, or both, was initiated by GPs in 62.3% of the 
cases and by psychiatrists in 36.2%. Medication was prescribed to 96.6% of the patients (593); 
with combinations of antidepressants and anxiolytics for 36.6%, antidepressants alone for 25.7%, 
and antidepressants, anxiolytics, and other medication for 7.9% being the most frequent. Other 
medications consisted of ant convulsants, antipsychotics, buspirone, and propanolol; and also 
passiflora, valerian and fentanyl. Overall 71.3%(438) of the patients received psychotherapy (not 
further specified), delivered respectively by psychiatrists (45.0%), GPs (36.8%), and 
psychologists (24.4%). 
Table III gives an overview of the duration and type of treatment, as well as the number and type 
of prescribed drugs, globally and for remitters and non-remitters. Interestingly, in the remission 
group, the proportion of patients taking anxiolytics was lower than in the group of non-remitters 
(8.5% vs. 20.1%, p< 0.0001, 2(1) = 17.13), while the converse occurred for patients taking 
antidepressants (14.7% vs. 4.0%, p= 0.011,2(1) = 6.46). The prevalence of remission did not 
differ between medicated and nonmedicated patients (13.4% vs.12.0%, p= 0.84, 2(1) = 0.041), 
nor between patients receiving psychotherapy and those who did not (13.6% vs. 13.0%, p= 0.85, 
2(1) = 0.035). GPs more often initiated therapy with medication alone (36.2% versus 17.9%), 
while psychiatrists more often initiated psychotherapy alone or a combination of medication and 
psychotherapy (6.0% versus 1.7% and 76.2% versus 62.2%, p< 0.0001). GPs more often 
prescribed anxiolytics (62.2% vs 52.2%, p= 0.013), while psychiatrists more often prescribed 
other medication (26.5% vs. 10.7%, p< 0.0001). Treatment duration was shorter in primary-care 
settings (4.8 months ± 4.7 vs. 6.1 months ± 4.9, p= 0.0016), while the number of prescribed 
drugs did not differ between the two groups. Data about the treatment duration were missing in 
4.5%, while no data were missing about the type of treatment. 
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Table 3. Treatment factors in the patients population (n= 618) and comparison between remitters and 
non-remitters. Percentages are given in parentheses. 
 
Discussion 
The present observational study aimed to establish the point prevalence of remission in patients 
with generalized anxiety during their first year of treatment delivered in both general and 
specialized-care settings, and to identify factors potentially impacting remission. Remission 
(HAM-A≤7) prevalence amounted 13.3%, and was found to be influenced by the occupational 
status of the patient and the severity of the current generalized anxiety episode, while 
diminishing proportionally with comorbid symptoms. The remitters had been in treatment for a 
longer time period, with lower remission rates in patients taking sedatives, but higher in those 
taking antidepressants. 
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A recent review of pharmacotherapy for generalized anxiety concluded that remission was 
attainable in over 50% of the patients treated (Davidson 2009). However, in line with Allgulander 
(2010), several considerations need to be addressed concerning the clinical trials reviewed. First, 
the demographic characteristics of most clinical-trial populations differ markedly from those 
reported here. The clinical-trial participants mostly ranged between 30 and 65 years with a mean 
age of 40 years, thus excluding elderly patients (Dubois et al. 2010). As this study incorporated 
patients over 65 years, the mean age was higher (46.8 years). This may partly explain the lower 
remission rate obtained, as older age is associated with poorer treatment outcome (Simon et al. 
2006). 
According to some studies, gender also tends to affect the course of generalized anxiety in that 
women are generally associated with lack of recovery (Rodriguez et al. 2006). Yet, in the present 
study, no gender-related differences in remission rate were found. In their 8-year follow-up 
study, Yonkers et al. (2000) also failed to find any such differences in the clinical course of 
generalized anxiety. 
Socioeconomic characteristics have been reported as significant risk factors with substantial 
consequences on generalized anxiety (Ansseau et al. 2008; Hunt et al. 2002; Pollack 2009). In line 
with Yonkers et al. (2000), living status and educational level were not found to be related to 
remission in this study. By contrast, for the first time, a positive association was demonstrated 
between remission and less-deprived socioeconomic status in the study patients, which is 
consistent with the literature on depression where higher income or full employment was also 
found to be associated with higher remission rates (Warden et al. 2009). 
DISEASE FACTORS 
Most patients who were evaluated in this study suffered from a moderate episode of generalized 
anxiety, that is, they were still capable of functioning to some (acceptable) extent despite 
manifesting clear anxiety symptoms impacting their functioning. As in the studies of Yonkers et 
al. (2003) and Penninx et al. (2011), we found higher remission prevalence in patients 
experiencing a mild episode. Moreover, the severity of illness and impairment were inversely 
associated with the likelihood of remission and recovery. 
Clinical trials tend to exclude patients with a comorbid psychiatric condition even though one of 
the main predictors for the clinical course of generalized anxiety is comorbidity (Weisberg 2009). 
Our results support this fact in that more than 40% of the patients without comorbidity achieved 
remission as opposed to those with comorbid symptoms (less than 10%). Furthermore, anxiety 
and depressive symptoms measured by the HADS were correlated with HAM-A scores. It should 
be noted, however, that the number of comorbidity-free patients in the present study was very 
small (n = 50). The majority of our patients (88.2%) had comorbid symptoms, reflecting the 
clinical reality that 90% of all patients with generalized anxiety present with at least one 
comorbid lifetime psychiatric disorder (Pollack 2009). The strength of the current study is thus 
its naturalistic design, permitting to gain more insight into remission rates in clinical practice as 
compared to those derived from clinical trials and experimental settings. 
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A remission rate of 13.3% is less than placebo response in most clinical trials so that one can even 
suggest that no active treatment has been provided on all in the current study. Indeed, according 
to Tonks (2003), low remission rates can in general also be attributed to the fact that the 
proportion of patients receiving the most appropriate or effective treatment is allegedly small. In 
the current study, treatment was left entirely to the discretion of the treating physicians and no 
inquiry was made about the rationale of the choice of treatment. Although the great majority of 
the patients had been prescribed antidepressants, no data were available about prescribed dose 
and treatment duration. Similarly, no data about the type and duration of psychotherapy were 
assembled, which makes it hard to evaluate the quality of treatment in the current study. 
Furthermore, low remission rates could not only be attributed to inferior prescription behaviour 
of the physician, but also to noncompliance of the patient. No data on the medication compliance 
in the pharmacotherapy group of the current study are available. 
In scientific literature, cognitive-behavioural therapy (CBT) and applied relaxation have been 
demonstrated to be more effective than placebo NICE (2011), but no systematic research is 
available showing CBT or applied relaxation to be comparable to other pharmacotherapy, nor a 
combination of CBT or applied relaxation and medication to be more effective than either stand-
alone treatment NICE (2011). 
Recovery rates of CBT and applied relaxation varied between 33% and 60% (Davidson 2009). We 
found no significant effects favoring one of the mentioned treatment schemes but, admittedly, the 
number of remitted patients receiving either psychotherapy or pharmacotherapy alone was very 
small. 
As the remission rate was found to be lower in patients taking anxiolytics and higher in those 
taking antidepressants, we referred to the recent reviews of therapies specific for generalized 
anxiety by Allgulander (2009), Davidson (2009), and Bandelow et al. (2012) who concluded that 
the efficacy of both psychological treatment and pharmacotherapy was comparable, but that 
efficacy differed among medication classes. The overall effect size of all medications for 
generalized anxiety disorder over that of placebo was 0.39 Allgulander (2009). According to the 
NICE guidelines, the strongest evidence for antidepressants, especially for SSRIs and SNRIs, 
makes them the drugs of choice in the treatment of generalized anxiety NICE (2011). In a recent 
metaanalysis, evidence for antidepressants was based on a total of 27 randomized controlled 
trials with effect size between 0.24 and 0.78 (compared with placebo). In this mixed treatment 
comparison by Baldwin et al., some estimates of the relative merits of differing compounds in 
achieving response and remission was reported. 
Benzodiazepines act more quickly and are, consequently, used more frequently (1) to attain 
immediate anxiolytic relief in the initiation of other treatments, (2) in episodes of symptom 
exacerbation, and (3) in treatment-resistant patients without a history of addiction Allgulander 
(2009). Long-term benzodiazepine use requires consistent monitoring for dependence or 
intolerance. Based on these facts, we may assume that patients taking anxiolytics during the 
study period suffered a severe episode or were more resistant to treatment, thus explaining their 
reduced likelihood of remission. To date, the most plausible explanation for the lower remission 
rate in the “anxiolytic” group remains the lower effectiveness of these types of agents in the 
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treatment of generalized anxiety. Unfortunately, owing to the low remission rate in both 
medication groups, we were unable to run detailed group analyses. 
The prevalence of remission was higher when treatment duration was longer, but longer 
treatment is a relative concept in our study as we mostly included patients who had received 
between 3 and 12 months of therapy. The remission prevalence in the patients treated longer 
than 12 months was lower than would be expected. Possibly, patients treated in excess of a year 
suffer from a more refractory disease type with residual symptoms in which remission is likely to 
occur. The remission group used fewer pharmacological agents, a well-known bias in 
observational studies: patients with the severest problems receive the most therapy, but are less 
likely to remit. Nevertheless, in their follow-up studies neither Bruce et al. (2005) nor Rodriguez 
et al. (2006) found any of the treatment factors to be predictive. The research reported was part 
of a naturalistic longitudinal study in which treatment effects were typically washed out and in 
which adjustment for treatment effects was complex.  
Although treatment in primary care is less appropriate than in psychiatric care with GPs 
prescribing more anxiolytics and initiating less-often psychotherapy during a shorter treatment 
duration, remission rates did not differ between primary and psychiatric care. A possible 
explanation is that patients treated by a psychiatrist suffer from a more-severe version of 
generalized anxiety demonstrated in the current study by a higher number of symptoms and a 
more-severe episode. In anxiety disorders, in general, Ormal et al. (1994) and de Graaf et al. 
(2010) already demonstrated underdiagnosis (and consequently undertreatment) by GPs result 
in poor remission rates for anxiety disorders in general. 
LIMITATIONS 
The evaluated patients with generalized anxiety were receiving treatment and therefore differed 
from the general population suffering from generalized anxiety with respect to disease severity, 
persistence, and comorbidity. Angst et al. (2009) postulated that treated patients suffer more 
distress and persistent anxiety and are more impaired at work by their anxiety. They are 
symptomatic for prolonged periods and suffer more frequently from concomitant type-2 bipolar 
disorder, social phobia, and cannabis dependence/abuse. Thus, although our findings cannot be 
generalized to the overall population suffering from generalized anxiety, our study sample is still 
representative of the clinical population, since we recruited patients from both primary and 
secondary care. Moreover, the patient characteristics are highly dependent on the general clinical 
policy adopted by Belgian GPs and psychiatrists; for instance, the prescription rate in Belgium is 
high and so is the use of benzodiazepines. 
Initially the study was designed to enrol 900 patients with generalized anxiety to allow for a 
reliable point-prevalence estimate of remission. In the end only 618 patients were recruited. 
An investigator guide including instructions for the HAM-A was provided to the participating 
physicians instead of a specific training. The lack of a specific training can have important 
consequences for the interrater reliability. On the other hand, the HAM-A has been shown good 
interrater reliability, even among inexperienced raters (Hamilton 1959; Bech et al. 1984) 
The present study primarily sought to evaluate patients having received 3–12 months’ treatment. 
We chose a minimum of 3 months as a time point where an optimal effect of the treatment can 
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first be expected. CBT and applied relaxation therapy usually consists of 12–15 weekly sessions. 
For pharmacotherapy with SSRIs or SNRIs, a response can be expected after 6–10 weeks NICE 
(2011). The fact that 26.8% of the study population had received less than or equal to 3 months 
of therapy can partly explain the low remission rates obtained. Furthermore, 3.2% of the patients 
had been in treatment for over 12 months, that is, beyond the acute phase of treatment. Such 
patients are more likely to suffer from a refractory disorder and residual symptoms making 
remission less probable. Overall, generalized anxiety runs a longitudinal course, involving 
recurrent remissions and recurrences. Since follow-up studies which monitored patients for 5 
years Warden et al. (2009) and 12 years Bruce et al. (2005) reported remission rates of 38% and 
58%, respectively, the choice of treatment period in this study may also account for the low 
remission rate. Accordingly, we believe that the results reported are largely representative of the 
population of adult outpatients with generalized anxiety in their first year of treatment. 
The participating physicians made no use of systematic diagnostic procedures. Patients were 
included if they were initially diagnosed by their physicians as suffering from generalized anxiety 
and if they were put under treatment for this reason. The dimension of generalized anxiety is 
questioned by use of a standardized symptom checklist during ongoing treatment, that is, 
retrospectively. Comorbid symptoms were questioned likewise which adds to the heterogeneity 
of the sample. Although a structural diagnostic interview might be the preferred method, it is 
almost never used in primary care and not systematically by psychiatrists. Moreover, the use of a 
structural diagnostic interview is not applicable in a cross-sectional design like ours, where 
prevalence of remission is measured, as it would preclude patients in (partial) remission. It 
should be noted, however, that patients who had already terminated their treatment were not 
included, which could also partially explain the low remission rate. 
Conclusion 
The present observational, non-interventional, cross-sectional study is one of the first to present 
results about the point prevalence of remission of generalized anxiety. The remission rate for 
Belgian patients with generalized anxiety during the first year of treatment amounted to 13.3%, 
much lower than would be expected. These findings once again underscore the need to improve 
the care for patients with generalized anxiety and are relevant for the prediction of prognosis in 
the first year of treatment. The two main limitations of the study are the lack of systematic 
diagnostic interviews and the use of a clinical sample of patients treated from 3 to 12 months. 
Therefore the results are only representative for a clinical population defined by key symptoms of 
generalized anxiety during the first year of the treatment. Large-scale studies are further needed 
to analyse the remitters in more detail, especially focusing on the effects of different medication 
classes and various types of psychotherapy. 
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 We measured the point prevalence of remission in patients treated for generalized 
anxiety and examined which factors affect this prevalence. The point prevalence was 
estimated at 13.3%. 
 The prevalence of remission was lower when the socioeconomic status was more 
deprived, comorbid symptoms were present, and the current generalized anxiety episode 
was more severe. 
 Medication use was also linked with remission prevalence. Remitters took fewer 
medications but were treated longer. Remission prevalence was higher in patients taking 
antidepressants than in those who did not, but was lower in patients taking sedatives. 
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